Analysis of immune response behavior and agents by vaccination with new coronavirus infections in patients with hematopoietic malignancies

Analysis of immune response behavior and agents by vaccination with new coronavirus infections in patients with hematopoietic malignancies - Evaluation of efficacy of new coronavirus vaccination in patients with hematopoietic malignancies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044850

Enrollment

Registered

2021-07-13

Start date

2021-07-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematopoietic malignancies

Interventions

Inoculate COVID-19 vaccine twice

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients over 20 years old 2. Patients with multiple myeloma, chronic myelogenous leukemia, or after allogeneic hematopoietic stem cell transplantation 3. Patients who have consented to COVID-19 vaccination 4. Patients who have obtained consent for this study by signing the consent form

Exclusion criteria

Exclusion criteria: 1. Patients who have difficulty or suffering from blood sampling and cannot tolerate multiple blood sampling 2. Patients with a history of vagal reflex 3. Patients who have already been vaccinated with COVID-19 vaccine 4. Patients with a history of SARS-CoV-2 infection

Design outcomes

Primary

Measure	Time frame
Rate of increase in SARS-CoV-2 antibody titer after COVID-19 vaccination	—

Countries

Japan

Contacts

Public ContactYasuyuki Nagata

Hamamatsu University School of Medicine Department of Internal Medicine III (Division of hematology)

yasu@hama-med.ac.jp+81-53-435-2267

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026